Wednesday, December 18, 2024

NIAID Funding News, December 18, 2024

NIH/NIAID Template Banner

December 18, 2024 NIAID Funding News

Read this full edition online at https://www.niaid.nih.gov/grants-contracts/funding-news?edition=2024-12-18

Feature Articles 

Tabulating NIAID's R01 and R21 Application and Award Counts for FY 2024

Each year, we share the number of R01-equivalent and R21 applications that NIAID received in the previous fiscal year as well as the number of grants NIAID awarded.

Opportunities and Resources

NIAID will support the development of safe and effective long-acting/sustained release technologies to help prevent and treat HIV and related co-infections such as tuberculosis, hepatitis B, and hepatitis C.

NIAID aims to foster new and innovative scientific endeavors related to universal influenza vaccine research to advance the major research areas defined in our Strategic Plan for the Development of a Universal Influenza Vaccine.

Advance our understanding of the impact of a host's microbial experience on the development and function of host immunity and provide the data necessary to encourage broader use of mouse models with diverse microbial experience in immunologic and microbiologic research.

Help ensure future effective global malaria control and elimination by focusing on "combination" vaccine concepts to improve efficacy, targeting one or more parasite antigens of the different life cycle stages of target parasites.

In The News

NIH's Advisory Committee to the Director (ACD) provides recommendations on program development, resource allocation, NIH administrative regulation, and other aspects of NIH policy.

News Briefs and Worth Repeating

  • Increased Interim Paylines for Fellowship, Career Development Awards
  • NIH Develops Training Resources for Responsible Conduct of Research
  • Enhance Your Presentations with High-Quality Science and Biomedical Art Illustrations

Advice Corner

Submitting complete and timely Federal Financial Reports is an important step to ensure NIAID's prompt review and consideration of any carryover requests.

Reader Questions

New Funding Opportunities

  • PA-25-301, NIH Research Project Grant (Parent R01, Clinical Trial Not Allowed)
  • PA-25-305, NIH Research Project Grant (Parent R01, Clinical Trial Required)
  • PA-25-304, NIH Exploratory/Developmental Research Project Grant (Parent R21, Clinical Trial Not Allowed)
  • PA-25-306, NIH Exploratory/Developmental Research Project Grant (Parent R21, Clinical Trial Required)
  • PA-25-302, NIH Small Research Grant Program (Parent R03, Clinical Trial Not Allowed)
  • RFA-AI-24-080, Broad Spectrum Products Against Multiple Neurotoxin Botulinum Serotypes (R61/R33, Clinical Trial Not Allowed)
  • PAR-25-296, Limited Competition: Clinical and Translational Science Award (CTSA) Program: Collaborative and Innovative Acceleration Award (UG3/UH3, Clinical Trial Optional)
  • PAR-25-330, Role of Defective Proviruses in HIV Persistence (R01, Clinical Trial Not Allowed)
  • PAR-25-298, Research Enhancement Award Program (REAP) for Health Professional Schools and Graduate Schools (R15, Clinical Trial Not Allowed)

Find other announcements at NIAID Opportunities and Announcements.

Send suggestions or comments to deaweb@niaid.nih.gov.


This email was sent to edwardlorilla1986.paxforex@blogger.com using GovDelivery Communications Cloud on behalf of: National Institute of Allergy and Infectious Diseases · 5601 Fishers Lane · Bethesda, MD 20892 · 1-866-284-4107 GovDelivery logo

No comments:

Post a Comment

Have you considered this for retirement?

Join my free course to learn about dividend portfolio basics. ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ͏  ...